Physician profile
Matthew A Kippe
NPI 1841491396
$30,950.61
in general payments reported to CMS, 2019-2025
15 companies · $4,232 in 2025
The $4,232 reported for 2025 was more than what 79% of Sports Medicine (Orthopaedic Surgery) providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,671 · 2020: $97.77 · 2021: $6,080 · 2022: $6,164 · 2023: $3,369 · 2024: $5,336 · 2025: $4,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,958 · Travel and Lodging: $4,207 · Food and Beverage: $2,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,958.18 |
| Travel and Lodging | $4,206.52 |
| Food and Beverage | $2,771.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $12,482.32 | 2019-2025 | |
| Catalyst Orthoscience | $9,808.54 | 2019-2025 | Catalyst Csr Shoulder System, Catalyst Total Csr, R1 Reverse Shoulder System |
| Kairos Surgical INC | $5,454.11 | 2019-2025 | |
| Zimmer Biomet Holdings, INC. | $1,648.22 | 2019-2023 | Comprehensive Shoulder System, Comprehensive, Choice Instruments |
| Depuy Synthes Sales INC. | $517.01 | 2024 | Inhance, Monovisc, Orthovisc |
| Kerecis Limited | $185.31 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Stryker Corporation | $181.69 | 2024 | Blueprint Patient Specific Instrumentation |
| Miach Orthopaedics, INC. | $173.53 | 2021 | |
| Medical Device Business Services, INC. | $139.70 | 2024 | Inhance |
| Encore Medical, LP | $116.20 | 2021 | |
| Polaris Technology Solutions LLC | $68.97 | 2025 | |
| Embody, INC. | $62.50 | 2022 | |
| Smith+Nephew, INC. | $46.32 | 2025 | |
| Axogen | $44.82 | 2025 | Axoguard Ha+ Nerve Protector |
| Vericel Corporation | $21.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$768,761.04 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Kippe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.